Elbion AG
Records under this name other than patents Elbion AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE38,624 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation Term ended Term ended Apr 28, 2019 · From the USPTO record | Term ended | Term ended Apr 28, 2019 | From the USPTO record |
| US 7,419,987 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them Formerly held Lapsed on the fee record Ended Sep 2, 2016 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2016 | From the USPTO record |
| US 7,947,705 | 7-azaindoles and the use thereof as therapeutic agents Formerly held Lapsed on the fee record Ended May 24, 2015 · From the USPTO record | Lapsed on the fee record | Ended May 24, 2015 | From the USPTO record |
| US 7,211,583 | 7-azaindoles and the use thereof as therapeutic agents Formerly held Lapsed on the fee record Ended May 1, 2015 · From the USPTO record | Lapsed on the fee record | Ended May 1, 2015 | From the USPTO record |
| US 7,169,787 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same Formerly held Lapsed on the fee record Ended Jan 30, 2015 · From the USPTO record | Lapsed on the fee record | Ended Jan 30, 2015 | From the USPTO record |
| US 7,875,618 | Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders Lapsed on the fee record Ended Jan 25, 2015 · From the USPTO record | Lapsed on the fee record | Ended Jan 25, 2015 | From the USPTO record |
| US 7,683,074 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them Formerly held Lapsed on the fee record Ended Mar 23, 2014 · From the USPTO record | Lapsed on the fee record | Ended Mar 23, 2014 | From the USPTO record |
| US 7,550,465 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them Lapsed on the fee record Ended Jun 23, 2013 · From the USPTO record | Lapsed on the fee record | Ended Jun 23, 2013 | From the USPTO record |
| US 7,309,713 | Use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowel syndrome Formerly held Lapsed on the fee record Ended Dec 18, 2011 · From the USPTO record | Lapsed on the fee record | Ended Dec 18, 2011 | From the USPTO record |
| US 6,613,794 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation Lapsed on the fee record Ended Sep 2, 2011 · From the USPTO record | Lapsed on the fee record | Ended Sep 2, 2011 | From the USPTO record |